DIRS.INFO The most relevant business & tech news

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ Amazon, CVS, and Walgreens went all in on primary care. Their bets are bleeding money.
▼ + stars: | 2024-03-06 | by ( ) www.businessinsider.com time to read: +8 min

In the past several years, Amazon, CVS Health, and Walgreens each spent billions to own primary-care companies. CVS bought Oak Street Health. Here's how the bets that Amazon, CVS, and Walgreens made are playing out. CVS is building more Oak Street clinics despite lossesAn Oak Street Health location in Elgin, Illinois during its grand opening. CVS is hoping to help Oak Street clinics get profitable quicker by driving more patients their way.

Persons: Andy Jassy, Thos Robinson, It's, JP Morgan, Berkshire Hathaway, Business Insider's Eugene Kim, Kim, they've, it's, VillageMD hasn't, Jefferies, Brian Tanquilut, Tanquilut, Lydia Ramsey, Mike Pykosz, Pykosz, Aetna, Michael Cherny Organizations: CVS Health, Walgreens, Amazon, CVS, Oak Street Health, Business, Aetna, Medical, Washington Post, Summit Health, Oak, Health Locations: Oak, VillageMD, Haven, Florida, Elgin , Illinois

☆ Stocks with high dividend growth and free cash flow perform best whatever the weather, Wolfe says
▼ + stars: | 2024-03-06 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that offer high dividend growth and high free cash flow perform best no matter the economic weather, according to Wolfe Research. Here are a few stocks that fit the bill, according to Senyek: Online marketplace eBay was one of several stocks that Wolfe singled out. With its 4% yield, CVS is also a good buy for investors focusing on a high-dividend growth, high free cash flow strategy, Wolfe said. Following CVS' earnings release, investment bank Leerink initiated research coverage of the stock with an outperform rating , citing its cash potential. Other stocks Wolfe included on its list were Constellation Energy , Humana and Archer-Daniels-Midland .

Persons: Chris Senyek, Wolfe, UnitedHealth, Andrew Mok, Tom Cowhey, — CNBC's Michael Bloom Organizations: Wolfe Research, eBay, Barclays, Medicare, CVS, Constellation Energy, Humana, Archer, Daniels, Midland

☆ 'Exciting idea': Fund manager loves this pharma stock — and analysts see more upside ahead
▼ + stars: | 2024-02-29 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

But one firm in the wider ecosystem that's perhaps lesser known stands out to fund manager Freddie Lait, which is McKesson Corp — the U.S. pharmaceuticals distribution company. Calling the company an "exciting idea," Lait noted that the 100-year-old business is "very defensive and very diversified." Lait manages over $750 million collectively between two funds — the Latitude Horizon Fund and the Latitude Global Fund . Of the 19 analysts covering the stock, 14 give it a buy or overweight rating, while three have hold ratings and one has a sell rating. The average price target on the stock is $550.25, according to FactSet data, giving it potential upside of 6%.

Persons: Eli Lilly, Freddie Lait, Lait, —, That's, … It's, McKesson, MCK, — CNBC's Michael Bloom Organizations: Novo Nordisk, Latitude Investment Management, CNBC, U.S, Cardinal Health, McKesson Corp, JPMorgan, Rite Aid, receivables, Leerink Partners, pharma

☆ Jim Cramer: Viking Therapeutics' weight-loss data not enough to dethrone Eli Lilly in GLP-1s
▼ + stars: | 2024-02-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.

Persons: CNBC's Jim Cramer, Eli Lilly —, —, Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly

☆ Here are Monday's biggest analyst calls: Nvidia, Alphabet, Salesforce, Arm, CVS, BJ's, Super Micro & more
▼ + stars: | 2024-02-26 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Morgan Stanley reiterates Target at overweight Morgan Stanley stood by its overweight rating on the department store owner. Morgan Stanley reiterates Salesforce as overweight Morgan Stanley said it likes the setup heading into earnings later this week. Morgan Stanley upgrades HashiCorp to overweight from equal weight Morgan Stanley said the software company has a compelling valuation. Morgan Stanley upgrades AvalonBay to overweight from equal weight Morgan Stanley said apartment REIT stocks like AvalonBay are '"cheap for a reason." Morgan Stanley upgrades Sun Country to overweight from equal weight Morgan Stanley said it likes the airline's business model.

Persons: Goldman Sachs, Goldman, Morgan Stanley, Salesforce, Rosenblatt, Jefferies, Amer, Wells, Jane Fraser, Roth MKM, Roth, TD Cowen, TD, DA Davidson, OW, Fannie Mae, KBW, Freddie, Truist, it's, Piper Sandler, Piper, Bentley Organizations: Nvidia, BMO, Apollo, Amer Sports, Citi, Citigroup, Bank of America, KKR, APO, BJ's Wholesale, D.A, Susquehanna, Energy, HSBC downgrades Moderna, HSBC, Moderna, Google, YouTube, " Bank of America, Omega Healthcare, Sun, DuPont's Mobility, JPMorgan, Navy, Bentley Systems Locations: USD75, Asana, ASAN

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Sitting on gains in Eli Lilly, Nvidia? Ask these questions before your next move
▼ + stars: | 2024-02-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

Eli Lilly has jumped almost 27%, building on its 59% gain in 2023. The long-term outlooks for Nvidia and Eli Lilly — both longtime Club holdings — brightened in recent weeks, leading to additional gains for the stocks. This leaves Club members who own Nvidia, Eli Lilly, or both, wondering how to proceed with their investments. Right now, we feel good about the timing of our most recent sales in Nvidia and Eli Lilly. Eli Lilly's stock is currently up about 24% from our Sept. 12 sale level, based on Thursday's close.

Persons: Eli Lily, Eli Lilly, Eli Lilly —, Eli Lilly's, Zepbound, Lilly's, Jim Cramer, Jim, There's, they're, Colette Kress, Goldman Sachs, FactSet, Lilly, Novo, Nordisk's Wegovy, tirzepatide, Jim Cramer's Organizations: Nvidia, Club, Apple, Microsoft, Web Services, Nordisk's, CNBC, Reuters Locations: Wall

☆ Here are Wednesday's biggest analyst calls: Nvidia, Apple, Target, Amazon, Quest, Deckers, Alphabet & more
▼ + stars: | 2024-02-07 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Jefferies initiates Sprout Social as buy Jefferies said the social media software provider is a market leader. Morgan Stanley names Huntington Bancshares a top pick Morgan Stanley said it likes the regional bank's low exposure to commercial real estate. Morgan Stanley reiterates Nvidia as overweight Morgan Stanley raised its price target on Nvidia to $750 per share from $603. Morgan Stanley downgrades Aptiv to underweight from equal weight Morgan Stanley said it sees slowing growth for the automotic tech company. Jefferies initiates ZoomInfo as buy Jefferies initiates the software data company with a buy and says it sees new customer growth.

Persons: Redburn, Key, it's, Gordon, Gordon Haskett, Jefferies, Steven Madden, Morgan Stanley, Huntington, Morgan Stanley downgrades Aptiv, Piper Sandler, Piper, Davidson, Goldman Sachs, Goldman, DA Davidson, it's bullish, Oppenheimer Organizations: Services, Bank of America, Google, Leerink, SPT, Citi, JPMorgan downgrades New York Community Bancorp, JPMorgan, Jefferies, Nvidia, Crown Holdings, Holdings, Civitas Resources, Corp, Vans, VF Corp, Bank of America downgrades, York Community Bancorp, New, Apple, Apple's Locations: F24E, New York

☆ Stocks making the biggest moves midday: Roblox, Enphase Energy, Snap, Alibaba and more
▼ + stars: | 2024-02-07 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

Adjusted earnings per share for the fourth quarter came in at 54 cents, slightly below the 55 cents expected from analysts polled by FactSet. Yum Brands — The restaurant stock added 3% despite Yum Brands' adjusted earnings and revenue miss for the fourth quarter. Adjusted earnings per share came in at 77 cents, topping the consensus estimate of 62 cents, according to FactSet. The company added about 300,000 net digital-only subscribers quarter over quarter, but advertising revenues came in below the company's guidance. Chipotle Mexican Grill — Shares added 8% a day after the fast-casual restaurant chain reported stronger-than-expected adjusted earnings and revenue.

Persons: Alessandro DiNello, Badri Kothandaraman, Alibaba, Amgen, Chipotle, Sonos, Walt Disney, Walt Disney's, Discovery, Fox, Alex Harring, Brian Evans, Sarah Min, Hakyung Kim Organizations: LSEG, New York Community Bank, Moody's Investors, New, Community, Enphase Energy, FactSet, Revenue, Yum Brands, KFC, Taco Bell, LSEG . Revenue, Leerink Partners, CVS, New York Times, Warner Bros, Discovery, Fox, Walt Disney's ESPN, Walt Disney, Disney, Cirrus Locations: LSEG ., Israel, Alibaba —, FactSet, FactSet .

☆ Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a mid-stage trial. The condition is characterized by excess fat build-up and inflammation in the liver and can lead to liver scarring, also known as fibrosis. The trial followed around 190 adults with MASH with severe stages of liver scarring, Eli Lilly executives said on an earnings call Tuesday. It was less clear how much the drug reduced liver scarring, which was the second aim of the trial. Eli Lilly is "equally encouraged" by tirzepatide's results in reducing liver scarring, the company's chief scientific officer Dan Skovronsky said on the call.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Dan Skovronsky, David Risinger, Eli Lilly's Organizations: Leerink, Novo Nordisk Locations: New York City, U.S

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Getting hot new weight-loss drugs like Wegovy will still be a struggle in 2024
▼ + stars: | 2024-01-04 | by ( ) www.businessinsider.com time to read: +11 min

AdvertisementIf you were hoping that powerhouse weight-loss drugs like Wegovy would be easier to get in 2024, you may be disappointed. Don't expect Medicare coverage any time soonMedicare could play a major role in expanding coverage of weight-loss drugs . Americans' hunger for weight-loss drugs, and the shockwaves it's likely to send through the culture and economy, are only just beginning. He oversees the state employee health plan, which saw costs skyrocket as thousands of workers suddenly started taking weight-loss drugs. People who are already getting weight-loss drugs will be able to keep taking them.

Persons: —, Renee Rayburg, Mercer, Eli Lilly's, Jose Luis Pelaez, there's, Wegovy, Bill Coyle, ZS, Eli Lilly, David Risinger, Lilly, Risinger, Morgan Stanley, Mounjaro, They're, That's, Patrik Jonsson, Lilly USA, Coyle, Dale Folwell, Folwell Organizations: Service, Pharmaceutical, Group, Novo Nordisk's Wegovy, Mayo Clinic, University of Texas, Hennepin Healthcare, Medicare, Capital Alpha Partners, Vanderbilt University, Nordisk's Wegovy, Novo Nordisk, pharma, Nordisk's, FDA, Pharma, UBS BioPharma Conference, Walmart, Jefferies, Nordisk Locations: Mounjaro, Government, Minnesota, Minneapolis, Hennepin, ZS, U.S, Carolina, North Carolina

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Medical device stocks rise in relief after Wegovy heart benefits data
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. That lifted shares of Penumbra (PEN.N), which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. "The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.

Persons: Victoria Klesty, Wegovy, Baird, Jeff Johnson, Eli Lilly's, Mike Kratky, Leroy Leo, Medha Singh, Sriraj Organizations: REUTERS, Novo, Devices, Abbott Laboratories, Thomson Locations: Oslo, Norway, Victoria, MedTech, Penumbra, Novo, Friday's, Bengaluru

☆ Weight-loss drugs just got cheaper — and better
▼ + stars: | 2023-11-11 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +7 min

Eli Lilly just debuted its powerful new weight-loss drug, Zepbound. Normally, when newer, better drugs are introduced, they match the price of similar drugs already available or come at a premium . Eli Lilly and Novo Nordisk have said that about 50 million people have some level of insurance coverage for weight-loss drugs. But some experts were skeptical, because employers and insurers don't typically pay the list price for drugs. Craig Garthwaite, an economist at Northwestern University, argued competition will drive the net prices of weight-loss drugs lower still.

Persons: Eli Lilly, —, Wegovy, LLY, It's, Mike Mason, coinsurance, Antonio Ciaccia, Crystal, We're, David Risinger, Dave Ricks, David Ricks, Eli Lilly's Mason, Mason, Craig Garthwaite, Garthwaite Organizations: Service, pharma, Nordisk's Wegovy, Ozempic, Deutsche Bank, 46brooklyn Research, Crystal Cox, Novo Nordisk, Zepbound, Wegovy, American Enterprise Institute, Northwestern University Locations: Mounjaro

☆ Never Mind Covid, Investors Want a Pfizer Obesity Pill
▼ + stars: | 2023-10-31 | by ( David Wainer | ) www.wsj.com time to read: +1 min

Pfizer says it hasn’t gotten the data on its experimental oral obesity medication. It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush , a healthcare strategist for Jefferies. Before today’s earnings, David Risinger , a Leerink Partners analyst, had written that Pfizer might even release data from its midstage study alongside the earnings results as soon as Tuesday.

Persons: hasn’t, Gabby Jones, Eli Lilly, ”, Will Sevush, Jefferies, David Risinger, Albert Bourla, TD Cowen, Steva Scala Organizations: Pfizer, The Wall, Novo Nordisk, Moderna, Partners

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

☆ Risky biotech M&A therapy will heal more fractures
▼ + stars: | 2023-10-19 | by ( Jonathan Guilford | ) www.reuters.com time to read: +8 min

NEW YORK, Oct 19 (Reuters Breakingviews) - How can a suitor offering $1 billion see eye-to-eye with a seller asking for $2 billion? Such contingent value rights, or CVRs, are a way to get around the inherent uncertainty of an unproven drug. Its $74 billion takeover of Celgene in 2019 included a $6.4 billion payout dependent on a trio of drug approvals. There have been only 27 biotech market debuts this year, raising $2.2 billion, according to LSEG data. Given the nagging fissures in valuation perspectives, however, more dealmakers are apt to try this risky M&A therapy.

Persons: Schulman, Sidley, Bristol Myers, Myers, CVRs, Andrew Weisenfeld, IPOs, ”, Dan Lepanto, biopharma, Eli Lilly’s, Bristol Myers Squibb, Jeffrey Goldfarb, Sharon Lam, Streisand Neto Organizations: Reuters, Dow, Marion Laboratories, LyondellBasell Industries, Mirati Therapeutics, JPMorgan, Sanofi, Health Partners, Nasdaq Biotechnology, Reuters Graphics Reuters, Reuters Graphics, Leerink Partners, Therapeutics, Public, Bristol Myers, U.S . Food, Drug Administration, Thomson Locations: Celgene, Genzyme, U.S

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products. Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook. Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023. Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Persons: Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru

☆ Here are Wednesday's biggest analyst calls: Nvidia, Boeing, SoFi, Netflix, Apple, Cava, Walmart and more
▼ + stars: | 2023-10-11 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Wednesday's biggest calls on Wall Street on Wednesday: Goldman Sachs upgrades Shoals to buy from neutral Goldman Sachs said the solar company is very attractive. Morgan Stanley upgrades Cava to overweight from neutral Morgan Stanley said it's gaining confidence in the restaurant chain. JPMorgan upgrades CSX to overweight from neutral JPMorgan said rail concerns have already played out. JPMorgan upgrades Iris Energy to overweight from neutral JPMorgan said the bitcoin mining company is "best-in-class." JPMorgan initiates CleanSpark as overweight JPMorgan said the bitcoin miner offers "relative value."

Persons: Goldman Sachs, Wells, Wells Fargo, TD Cowen, Cowen, Stephens, Raymond James, it's bullish, Morgan Stanley, Cava, it's, UBS downgrades Morgan Stanley, Oppenheimer, Needham, Robinhood, MAUs, Truist, Piper Sandler, JPMorgan, Mizuho, SoFi, SOFI, Leerink, Apple Organizations: Netflix, JPMorgan, CSX, Nvidia, Iris Energy, Energy, UBS, Boeing, Oppenheimer downgrades Texas, Texas, Qs, Logistics, Amazon, Arista Networks, Barclays, Ball Corporation, Apple, Walmart, Deutsche Bank, Cboe Locations: CAVA, OW, U.S, China, ANET, SoFi

☆ Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and more
▼ + stars: | 2023-10-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Plug Power — The battery stock added nearly 6% after the company projected a sharp rise in revenue by 2027 to roughly $6 billion, according to a regulatory filing. DaVita , Novo Nordisk — Shares of the dialysis services provider sank 15% on the news of Ozempic's effectiveness in Novo Nordisk's kidney disease treatment study. Exxon Mobil, Pioneer Natural Resources – Shares of Exxon Mobil were lower by more than 1% premarket after the company agreed to buy Pioneer for nearly $60 billion, or $253 per share, in an all-stock merger. Meanwhile, Pioneer shares rose 2.5%. CSX — Shares added nearly 2% after an upgrade to overweight from JPMorgan.

Persons: Michael Feniger, Raymond James, Humana, Bruce Broussard, Sherwin, Williams, Heidi G, Petz, David Risinger, Macheel, Pia Singh, Michelle Fox Organizations: Mobil, Bank of America, Novo Nordisk —, Novo Nordisk, Exxon Mobil, Natural, Exxon, CSX, JPMorgan, Leerink Partners Locations: Los Angeles , California, Novo

☆ Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and more
▼ + stars: | 2023-10-11 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic's kidney disease treatment trial after a committee said an analysis showed signs of success. DaVita , Fresenius Medical Care , Baxter International — Shares of dialysis services providers DaVita and Fresenius Medical Care sank 18.4% and 19.6%, respectively, on Novo Nordisk's news. Exxon Mobil , Pioneer Natural Resources — Exxon Mobil shares fell more than 4% after the largest U.S. oil and gas producer agreed to buy shale rival Pioneer Natural Resources for $59.5 billion in an all-stock deal, or $253 per share. Amgen — The biopharma stock added 3.5% following an upgrade from Leerink to outperform. On Wednesday, B. Riley upgraded shares to buy from neutral, saying Coherent's silicon carbide business could be worth more than the Street's current estimate.

Persons: Eli Lilly, Bruce Broussard, Jim Rechtin, Amgen, David Risinger, Goldman Sachs, Jeffrey Brown, Tim Wentworth, Riley, Raymond James, — CNBC's Michael Bloom, Hakyung Kim, Yun Li, Lisa Han Organizations: Novo Nordisk, Novo Nordisk —, Baxter, Fresenius, Novo Nordisk's, Baxter International, Exxon Mobil, Natural Resources, Exxon, Exxon's, Mobil, Healthcare, Goldman, Walgreens, Alliance Locations: Danish, Novo

Search resuls for: "Leerink"

25 mentions found